D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, vol.12, issue.4, pp.252-64, 2012.

F. S. Hodi, O. Day, S. J. Mcdermott, D. F. Weber, R. W. Sosman et al., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, N Engl J Med, vol.363, issue.8, pp.711-734, 2010.
DOI : 10.1056/nejmoa1003466

URL : http://www.nejm.org/doi/pdf/10.1056/NEJMoa1003466

J. R. Brahmer, S. S. Tykodi, L. Chow, W. Hwu, S. L. Topalian et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, vol.366, issue.26, pp.2455-65, 2012.

S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith et al., Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer, N Engl J Med, vol.366, issue.26, pp.2443-54, 2012.

A. Guizard, B. Trétarre, and A. Woronoff, Survie des personnes atteintes de cancer en France métropolitaine 1989-2013 / Partie 1-Tumeurs solides

R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin, vol.65, issue.1, pp.5-29, 2015.
DOI : 10.3322/caac.21254

URL : https://onlinelibrary.wiley.com/doi/pdf/10.3322/caac.21254

S. N. Westin, R. A. Lacour, D. L. Urbauer, R. Luthra, D. C. Bodurka et al., Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome, J Clin Oncol Off J Am Soc Clin Oncol, vol.26, issue.36, pp.5965-71, 2008.

J. A. Lachance, E. N. Everett, B. Greer, L. Mandel, E. Swisher et al., The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer, Gynecol Oncol, vol.101, issue.3, pp.470-475, 2006.

S. Jolly, C. E. Vargas, T. Kumar, S. A. Weiner, D. S. Brabbins et al., The impact of age on longterm outcome in patients with endometrial cancer treated with postoperative radiation, Gynecol Oncol, vol.103, issue.1, pp.87-93, 2006.

H. Werner, J. Trovik, J. Marcickiewicz, S. Tingulstad, A. C. Staff et al., Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification, Gynecol Oncol, vol.125, issue.1, pp.103-111, 2012.

D. S. Mcmeekin, D. Lashbrook, M. Gold, G. Johnson, J. L. Walker et al., Analysis of FIGO Stage IIIc endometrial cancer patients, Gynecol Oncol, vol.81, issue.2, pp.273-281, 2001.

N. Colombo, E. Preti, F. Landoni, S. Carinelli, A. Colombo et al., Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.24, issue.6, pp.33-41, 2013.

I. Barillot, C. Haie-méder, C. Brunaud, C. Peignaux, K. Kerr et al., Radiothérapie des cancers du col et de l'endomètre. Cancer/Radiothérapie, pp.189-95, 1920.

I. Diaz-padilla, N. Romero, E. Amir, X. Matias-guiu, E. Vilar et al., Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis, Crit Rev Oncol Hematol, vol.88, issue.1, pp.154-67, 2013.
DOI : 10.1016/j.critrevonc.2013.03.002

H. Hampel, W. Frankel, J. Panescu, J. Lockman, K. Sotamaa et al., Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients, Cancer Res, vol.66, issue.15, pp.7810-7817, 2006.
DOI : 10.1158/0008-5472.can-06-1114

URL : http://cancerres.aacrjournals.org/content/canres/66/15/7810.full.pdf

H. F. Vasen, P. Watson, J. P. Mecklin, and H. T. Lynch, New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC, Gastroenterology, vol.116, issue.6, pp.1453-1459, 1999.

J. Shia, S. Holck, G. Depetris, J. K. Greenson, and D. S. Klimstra, Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry. Fam Cancer, vol.12, pp.241-60, 2013.

A. Umar, C. R. Boland, J. P. Terdiman, S. Syngal, A. De-la-chapelle et al., Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability, J Natl Cancer Inst, vol.96, issue.4, pp.261-269, 2004.

G. S. Nelson, A. Pink, S. Lee, G. Han, D. Morris et al., MMR deficiency is common in highgrade endometrioid carcinomas and is associated with an unfavorable outcome, Gynecol Oncol, vol.131, issue.2, pp.309-323, 2013.

A. Shikama, T. Minaguchi, K. Matsumoto, A. Akiyama-abe, Y. Nakamura et al., Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas, Gynecol Oncol, vol.140, issue.2, pp.226-259, 2016.

I. Ruiz, M. Martín-arruti, E. Lopez-lopez, and A. Garcia-orad, Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type, Gynecol Oncol, vol.134, issue.1, pp.20-23, 2014.

D. S. Mcmeekin, D. L. Tritchler, D. E. Cohn, D. G. Mutch, H. A. Lankes et al., Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study, J Clin Oncol Off J Am Soc Clin Oncol, vol.34, issue.25, pp.3062-3070, 2016.

D. T. Le, J. N. Uram, H. Wang, B. R. Bartlett, H. Kemberling et al., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N Engl J Med, vol.372, issue.26, pp.2509-2529, 2015.

A. Vanderstraeten, C. Luyten, G. Verbist, S. Tuyaerts, and F. Amant, Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy, Cancer Immunol Immunother, vol.63, issue.6, pp.545-57, 2014.

C. Network, C. Kandoth, N. Schultz, A. D. Cherniack, R. Akbani et al., Integrated genomic characterization of endometrial carcinoma, Nature, vol.497, issue.7447, pp.67-73, 2013.

B. Rousseau, S. Champiat, D. Loirat, J. Arrondeau, N. Lemoine et al., Immunothérapies et thérapies ciblées en oncologie médicale : rationnel d'essai d'association et perspectives, Bull Cancer, vol.101, issue.1, pp.31-40, 2014.

K. E. Visser and L. M. Coussens, The inflammatory tumor microenvironment and its impact on cancer development, Contrib Microbiol, vol.13, pp.118-155, 2006.

B. Engels, V. H. Engelhard, J. Sidney, A. Sette, D. C. Binder et al., Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell, vol.23, pp.516-542, 2013.

N. Vigneron, V. Stroobant, B. J. Van-den-eynde, and P. Van-der-bruggen, Database of T cell-defined human tumor antigens: the 2013 update, Cancer Immun, vol.13, p.15, 2013.

F. M. Burnet, The concept of immunological surveillance, Prog Exp Tumor Res, vol.13, pp.1-27, 1970.

G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, Cancer immunoediting: from immunosurveillance to tumor escape, Nat Immunol, vol.3, issue.11, pp.991-999, 2002.

G. P. Dunn, L. J. Old, and R. D. Schreiber, The Immunobiology of Cancer Immunosurveillance and Immunoediting, Immunity, vol.21, issue.2, pp.137-185, 2004.

G. Menderes, C. Hicks, J. D. Black, C. L. Schwab, and A. D. Santin, Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers, Expert Opin Biol Ther, vol.16, issue.8, pp.989-1004, 2016.

S. A. Rosenberg, Progress in human tumour immunology and immunotherapy, Nature, vol.411, issue.6835, pp.380-384, 2001.

R. M. Zinkernagel, Immunity against solid tumors?, Int J Cancer, vol.93, issue.1, pp.1-5, 2001.

F. Klemm and J. A. Joyce, Microenvironmental regulation of therapeutic response in cancer, Trends Cell Biol, vol.25, issue.4, pp.198-213, 2015.

S. Dushyanthen, P. A. Beavis, P. Savas, Z. L. Teo, C. Zhou et al., Relevance of tumorinfiltrating lymphocytes in breast cancer, BMC Med, vol.13, 2015.

W. H. Fridman and C. Sautès-fridman, Le microenvironnement tumoral: Matrice nourricière, champ de bataille et cible thérapeutique des cancers. médecine/sciences, vol.30, pp.359-65, 2014.

P. Sharma and J. P. Allison, The future of immune checkpoint therapy, Science, vol.348, issue.6230, pp.56-61, 2015.

K. C. Ohaegbulam, A. Assal, E. Lazar-molnar, Y. Yao, and X. Zang, Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway, Trends Mol Med, vol.21, issue.1, pp.24-33, 2015.

H. Dong, G. Zhu, K. Tamada, and L. Chen, B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion, Nat Med, vol.5, issue.12, pp.1365-1374, 1999.

M. E. Keir, S. C. Liang, I. Guleria, Y. E. Latchman, A. Qipo et al., Tissue expression of PD-L1 mediates peripheral T cell tolerance, J Exp Med, vol.203, issue.4, pp.883-95, 2006.

A. L. Kinter, E. J. Godbout, J. P. Mcnally, I. Sereti, G. A. Roby et al., The common gammachain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands, J Immunol Baltim Md, vol.181, issue.10, pp.6738-6784, 1950.

Z. Dong, S. Wu, R. Liao, S. Huang, and Y. Wu, Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. Tumor Biol, vol.37, pp.4251-61, 2016.
DOI : 10.1007/s13277-016-4812-9

M. Z. Noman, G. Desantis, B. Janji, M. Hasmim, S. Karray et al., PD-L1 is a novel direct target of HIF-1?, and its blockade under hypoxia enhanced MDSC-mediated T cell activation, J Exp Med, vol.211, issue.5, pp.781-90, 2014.

Y. Zhang, S. Kang, J. Shen, J. He, L. Jiang et al., Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a metaanalysis. Medicine (Baltimore), vol.94, p.515, 2015.

K. Chen, G. Cheng, F. Zhang, N. Zhang, D. Li et al., Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma, Oncotarget, 2016.

R. H. Thompson, S. M. Kuntz, B. C. Leibovich, H. Dong, C. M. Lohse et al., Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up, Cancer Res, vol.66, issue.7, pp.3381-3386, 2006.

C. Yang, M. Lin, Y. Chang, C. Wu, Y. et al., Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma, Eur J Cancer, vol.57, pp.91-103, 2016.

L. H. Schmidt, A. Kümmel, D. Görlich, M. Mohr, S. Bröckling et al., PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups, PloS One, vol.10, issue.8, p.136023, 2015.

A. Fusi, L. Festino, G. Botti, G. Masucci, I. Melero et al., PD-L1 expression as a potential predictive biomarker, Lancet Oncol, vol.16, issue.13, pp.1285-1292, 2015.
DOI : 10.1016/s1470-2045(15)00307-1

M. Teng, S. F. Ngiow, A. Ribas, and M. J. Smyth, Classifying Cancers Based on T-cell Infiltration and PD-L1, Cancer Res, vol.75, issue.11, pp.2139-2184, 2015.
DOI : 10.1158/0008-5472.can-15-0255

URL : http://cancerres.aacrjournals.org/content/75/11/2139.full.pdf

P. C. Tumeh, C. L. Harview, J. H. Yearley, I. P. Shintaku, E. Taylor et al., PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, issue.7528, pp.568-71, 2014.
DOI : 10.21417/b7z59d

URL : http://europepmc.org/articles/pmc4246418?pdf=render

W. H. Fridman, J. Galon, F. Pagès, E. Tartour, C. Sautès-fridman et al., Prognostic and predictive impact of intra-and peritumoral immune infiltrates, Cancer Res, vol.71, issue.17, pp.5601-5606, 2011.
DOI : 10.1158/0008-5472.can-11-1316

URL : http://cancerres.aacrjournals.org/content/71/17/5601.full.pdf

W. H. Fridman, F. Pagès, C. Sautès-fridman, and J. Galon, The immune contexture in human tumours: impact on clinical outcome, Nat Rev Cancer, vol.12, issue.4, pp.298-306, 2012.

B. Mlecnik, M. Tosolini, A. Kirilovsky, A. Berger, G. Bindea et al., Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction, J Clin Oncol Off J Am Soc Clin Oncol, vol.29, issue.6, pp.610-618, 2011.

T. M. Therneau, Extending the Cox model, Mayo Clinic, 1996.
DOI : 10.1007/978-1-4684-6316-3_5

. Pd-1, PD-L1 expression in 1599 gynecological cancers: Implications for immunotherapy, 2016.

Y. Katsuya, Y. Fujita, H. Horinouchi, Y. Ohe, S. Watanabe et al., Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer, vol.88, pp.154-163, 2015.
DOI : 10.1016/j.lungcan.2015.03.003

S. Cedrés, S. Ponce-aix, J. Zugazagoitia, I. Sansano, A. Enguita et al., Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM), PloS One, vol.10, issue.3, p.121071, 2015.

W. Y. Sun, Y. K. Lee, and J. S. Koo, Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies, J Transl Med, vol.14, issue.1, p.173, 2016.

K. M. Kerr and M. C. Nicolson, Non-Small Cell Lung Cancer, PD-L1, and the Pathologist, Arch Pathol Lab Med, vol.140, issue.3, pp.249-54, 2016.
DOI : 10.5858/arpa.2015-0303-sa

M. M. Awad and P. S. Hammerman, Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers, J Clin Oncol Off J Am Soc Clin Oncol, vol.33, issue.18, pp.1993-1997, 2015.
DOI : 10.1200/jco.2015.61.4172

R. K. Beckers, C. I. Selinger, R. Vilain, J. Madore, J. S. Wilmott et al., Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome, Histopathology, vol.69, issue.1, pp.25-34, 2016.
DOI : 10.1111/his.12904

J. R. Webb, K. Milne, D. R. Kroeger, and B. H. Nelson, PD-L1 expression is associated with tumorinfiltrating T cells and favorable prognosis in high-grade serous ovarian cancer, Gynecol Oncol, vol.141, issue.2, pp.293-302, 2016.
DOI : 10.1016/j.ygyno.2016.03.008

URL : https://manuscript.elsevier.com/S0090825816300658/pdf/S0090825816300658.pdf

L. Chen, Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity, Nat Rev Immunol, vol.4, issue.5, pp.336-383, 2004.

T. Suemori, N. Susumu, T. Iwata, K. Banno, W. Yamagami et al., , p.8

, Lymphocyte Infiltration as a Prognostic Factor and Its Relationship With Cyclooxygenase 2 Expression and Microsatellite Instability in Endometrial Cancer, Int J Gynecol Cancer Off J Int Gynecol Cancer Soc, vol.25, issue.7, pp.1165-72, 2015.

R. A. De-jong, N. Leffers, H. M. Boezen, K. A. Ten-hoor, A. Van-der-zee et al., Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer, Gynecol Oncol, vol.114, issue.1, pp.105-115, 2009.